Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market cap$50M–$500B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Thursday, October 22, 2026· 9581 stock ideas· 219 writers·
23,415 views· 11,117 clicks

Lam Research Q1 FY6/27 Earnings Review

Lam Research reported $8.22 billion in Q1 FY6/27 revenue, with systems up 62% and operating margin reaching a record 40% as memory spending accelerated.

LRCX $326B
Cestrian Capital Research 4 clicks

From X

@BrokenMoats

Broken Moats on X

$BSX ?? flat over the past 5 years. Can point to slowing growth from very elevated levels as farapulse and watchman have larger bases, some competition entering these spaces, glp1 on the margin to case loads over time, new inhibitors that could be coming from Lilly, novo, but at current $ sure seems like a lot is baked in at current prices. Innovative cardio franchise that has: Revenue has effectively doubled - predominately from farapulse and watchman (not m&a) Operating income 1.8B to 4.1B EBIT - $1.4B to 4.1B 3.5x on EPS (.69 to $2.40/share current) gross, operating, net, ebit, ebitda margins all expanded over that timeframe FCF more than 2x, opcf 2.5x The difference is you get to buy it at the same share price today, shares outstanding are virtually flat. Perhaps the defensive nature of medtech is sold in the aggressive risk on market we are in but growth still solid here with dividend and margin of safety versus other areas certainly seems worth a look, as is the rest of medtech as a place to hunt for value to wait until the market rotates back
@BrokenMoats 1 click

Broken Moats on X

Pretty incredible market sells off software again aggressively at the same time ramping up public private credit exposed names like $MFC, $ARES, $FG (CEO left suddenly yesterday) all because they ride alongside the aggressive buying in money center banks in financial etc flows ($JPM up 14% in June). Seems like there needs to be some dispersion in public private credit and software - one side at current prices has to be wrong, guessing private credit lower is how the dispersion resolves itself
@BrokenMoats

Broken Moats on X

Intensity and rapidness of recent moves is worth acknowledging. Not sure what to make of it. I understand the concept of oil/rates lower improving the backdrop for consumer discretionary but its not as if oil had not been trending lower for weeks, the deal always seemed more priced in versus priced out of markets *and china and us, Japan heavily released reserves to temper oil - so outside front month price movement - oil has been massaged lower for quite some time* Trying to understand what sets off names besides the incremental delta of lower rates.oil to send retail oriented names up 30-50% in a week or two? $ELF $CAVA $SHAK etc and some of these reported weak sales with lowered outlooks. Shak as recently as <2 weeks ago $MGNI - heavy insider selling past few days, stock is 30%+ in short time frame ELF $48-$70 in basically a week CAVA - $70-$92 in a few days -- $bros, shak similar moves $BIRK - pure short squeeze off float dynamics, but stock basically up 60% in a few weeks. Certainly a different market, but not sure its healthy to either see these names artificial pinned down in relation to the rest of the market narrative or react to slight incremental news with the some of the biggest runs in each individual companies entire trading history.....
@BrokenMoats

Broken Moats on X

$SLP buyout today ends an ugly few years for the company. The core simulation software business, even in this ai world, still presents lots of value as key models are used by the FDA in drug approval process. But the management team after the founder stepped back destroyed the company with one destructive acquisition after another. Diluted the software with a heavy concentration on commoditized services revenue and less differentiated software assets, all purchased at high multiples to show "revenue growth". Mgmt destroyed the free cash flow, decimated the share price over the tenure but did allow management to rack up steadily increased compensation for themselves by growing the "size" of the company. A good case study in how poor management can take a wide moat business and turn it into a lousy one pretty fast. I imagine the new PE owners can extract out the bad business and excessive costs and generate a good return focusing on the original assets.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Mosaic, Part One: The Story

Mosaic’s history traces the 2004 Cargill-IMC merger and the phosphate and potash mines that shaped NYSE: MOS.

MOS $5.7B
Latticework by MOI Global 7 clicks

Mosaic, Part Two: The Deep Dive

Mosaic, NYSE: MOS, is the subject of a second audio program for professional investors analyzing fertilizer producers.

MOS $5.7B
Latticework by MOI Global 4 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $110M
Triple S Special Situations Investing 3 clicks
UNCY · long

Unicycive Therapeutics INC

Unicycive Therapeutics fell nearly 50% after a second FDA Complete Response Letter tied to a third-party manufacturer for its primary…

UNCY $110M
Value Investors Club

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $291M
Guardian Research 3 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite…

SVM $2B
The Oak Bloke 27 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Wednesday, October 21 54 stock ideas
  • Why I sold OB pick for 26 SVM The Oak Bloke
  • CoreWeave: It’s Not Dying, Not Anytime Soon Capitalist Letters
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 54 of 247

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

190 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick